Avalyn Pharma Inc.
AVLNNasdaqCIK 1540171HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: Q2 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPS−$0.98Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.98 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-345820.Report this figure+94.4% on a year earlier - Free cash flow−$26.3mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$26.1m. XBRL concept
us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-345820. Derived: 6-month figure less the 3-month figure.Capital expenditure: $269.0k. XBRL conceptus-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001193125-26-345820. Derived: 6-month figure less the 3-month figure.Report this figure−27.3% on a year earlier
Last eight quarters
Full statements| Line item | Unit | period not labelled2025-03-31 | period not labelled2025-06-30 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|
| Revenue | $m | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (63.24)Diluted EPS, period not labelled, three months to 2025-03-31−$63.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-06-03, accession 0001193125-26-254623.Report this figure | (17.63)Diluted EPS, period not labelled, three months to 2025-06-30−$17.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-345820.Report this figure | (21.83)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$21.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-06-03, accession 0001193125-26-254623.Report this figure | (0.98)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-345820.Report this figure | |
| Free cash flow | $m | (19.3)Free cash flow, period not labelled, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$19.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-06-03, accession 0001193125-26-254623.Capital expenditure: $8.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-06-03, accession 0001193125-26-254623.Report this figure | (20.7)Free cash flow, period not labelled, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$20.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-345820. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001193125-26-345820. Derived: 6-month figure less the 3-month figure.Report this figure | (30.2)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$29.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-06-03, accession 0001193125-26-254623.Capital expenditure: $318.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-06-03, accession 0001193125-26-254623.Report this figure | (26.3)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$26.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-345820. Derived: 6-month figure less the 3-month figure.Capital expenditure: $269.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001193125-26-345820. Derived: 6-month figure less the 3-month figure.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| FMR LLC | 2026-06-30 | $192.1m | 5,835,259 | New+5,835,259 | |
| NOVO HOLDINGS A/S | 2026-06-30 | $127.8m | 3,883,289 | New+3,883,289 | |
| SR One Capital Management, LP | 2026-06-30 | $108.9m | 3,308,649 | New+3,308,649 | |
| PERCEPTIVE ADVISORS LLC | 2026-06-30 | $88.1m | 2,675,296 | New+2,675,296 | |
| MONTANOVA CAPITAL, LLC | 2026-06-30 | $82.4m | 2,503,109 | New+2,503,109 | |
| NVP ASSOCIATES, LLC | 2026-06-30 | $74.7m | 2,268,404 | New+2,268,404 | |
| WELLINGTON MANAGEMENT GROUP LLP | 2026-06-30 | $72.5m | 2,201,986 | New+2,201,986 | |
| Catalio Capital Management, LP | 2026-06-30 | $55.2m | 1,675,830 | New+1,675,830 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 2026-06-30 | $45.3m | 1,375,486 | New+1,375,486 | |
| Bellevue Group AG | 2026-06-30 | $44.4m | 1,350,000 | New+1,350,000 |
Recent filings
All 63 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1616:13 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-393081 |
| 2026-08-1208:15 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-345820 |
| 2026-08-1208:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-345807 |
| 2026-07-0117:20 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-292834 |
| 2026-06-1708:03 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-26-273405 |
| 2026-06-0308:00 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-254623 |
| 2026-06-0307:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-254581 |
| 2026-05-0818:52 ET | SCHEDULE 13D | Ownership report, active investor | 0000899140-26-000428 |
| 2026-05-0816:41 ET | SCHEDULE 13D | Ownership report, active investor | 0001072613-26-000386 |
| 2026-05-0116:09 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-201434 |
Latest annual report
No annual report is in coverage for this company.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1540171
- Tickers
- AVLN
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- DE
- Filer category
- <br>Emerging growth company
- Former names
- Genoa Pharmaceuticals, Inc. (to 2017-05-24)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.